Skip to content

Dr. Eric Shiozaki

Partner, DCVC Bio

Eric is focused on identifying disruptive tech­nolo­gies that have the potential to open new frontiers in healthcare. With an emphasis on drug development and medical tech­nolo­gies, he works closely with entre­pre­neurs to build companies whose mission is to advance the practice of medicine and promote human health. 

Prior to joining DCVC Bio, Eric was a Partner at Novo Ventures where he established and managed the firm’s public equities strategy focused on SMID-Cap and late-stage private companies in biotech and medtech. Earlier in his career, Eric was a Director at Apposite Capital and an Associate at Burrill & Company. Having initially trained as a structural biologist, he served as a Leukemia & Lymphoma Society Post-Doctoral Fellow. Eric received a bachelor’s degree in biophysics from Johns Hopkins University and a PhD in molecular biology from Princeton University.